181. Studying the effect of self-care education based on conceptual mapping on the pain severity of patients with rheumatoid arthritis: A non-randomized quasi-experimental study.
作者: Nasrin Rasoulzadeh.;Navid Dadashi.;Zahra Rooddehghan.;Raoofeh Karimi.
来源: BMC Rheumatol. 2025年9卷1期107页
Rheumatoid arthritis is a chronic and progressive disease, the most important and common symptom of which is pain. Considering the physical and psychological effects of pain on health and well-being, it seems that finding new methods such as conceptual mapping to teach self-care to patients is important for controlling and reducing pain. This study was conducted to determine the effect of self-care education based on conceptual mapping on the pain severity of patients with rheumatoid arthritis.
182. Effect of writing based on self-compassion on body image and psychological distress among women with systemic lupus erythematosus: a randomized clinical trial.
作者: Kimya Amouei.;Arpi Manookian.;Seyedeh Tahereh Faezi.;Leila Sayadi.
来源: BMC Rheumatol. 2025年9卷1期106页
Women with systemic lupus erythematosus (SLE) are at risk for body image (BI) disturbances and its resultant psychological distress (PD). The aim of this study was to examine the effects of self-compassion (SC)-based writing on BI and PD among women with SLE.
183. Associations of PTPN22 and PADI4 polymorphisms with rheumatoid arthritis in ASWAN.
作者: Khaled A A Abdelgalil.;Nihal Fathi.;Fatma H El Nouby.;Nour A Mohammed.;Loay I Aglan.
来源: BMC Rheumatol. 2025年9卷1期105页
Rheumatoid Arthritis (RA) is a prevalent autoimmune disease affecting approximately 84,338 individuals in Egypt. Genetic predispositions, such as the PTPN22 and PADI4 genes, are linked to RA risk. PTPN22, a protein tyrosine phosphatase, a regulator of T-cell receptor signalling and PADI4, which is involved in citrullination, have shown varying levels of association with RA across populations. Studies have been inconclusive regarding their roles in RA susceptibility, progression, and activity.
184. Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years.
作者: Philip J Mease.;Laura C Coates.;Corine Gaillez.;Alexis Shew.;Weibin Bao.;Christopher T Ritchlin.
来源: Rheumatology (Oxford). 2026年65卷1期
To examine relationships between radiographic progression and achievement of low disease activity (LDA) or remission at week 104 in patients with PsA receiving secukinumab.
185. Differences in spinal structural lesions between patients with early axSpA and non-axSpA chronic back pain: 2-year SPACE cohort results.
作者: Gizem Ayan.;Liese de Bruin.;Miranda van Lunteren.;Manouk de Hooge.;Ana Bento da Silva.;Mary Lucy Marques.;Monique Reijnierse.;Victoria Navarro-Compán.;Marleen van de Sande.;Inger Jorid Berg.;Roberta Ramonda.;Sofia Exarchou.;Désirée van der Heijde.;Floris van Gaalen.;Sofia Ramiro.
来源: Rheumatology (Oxford). 2026年65卷1期
To compare spinal structural lesions on radiography and magnetic resonance imaging (MRI) over 2 years, between patients with early axial spondyloarthritis (axSpA) and non-axSpA chronic back pain.
186. The global, regional, and national burden attributable to low bone mineral density, 1990-2020: an analysis of a modifiable risk factor from the Global Burden of Disease Study 2021.
Fractures related to osteoporosis and low bone mineral density lead to substantial morbidity, mortality, and cost to individuals and health systems. Here we present the most up-to-date global, regional, and national estimates of the contribution of low bone mineral density to the burden of fractures from falls and additional categories of injuries from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021.
187. Methylprednisolone plus MTX-based regime vs prednisone-based standard of care for GCA: a propensity score study.
作者: Adriana Soto-Peleteiro.;José Hernández-Rodríguez.;Fátima Raad.;Borja de Miguel.;Leonor Acha.;Marina Torio.;Halbert Hernandez-Negrin.;Verónica Gómez-Caverzaschi.;Ioana Ruiz-Arruza.;Olga Araujo.;Sergio Prieto-González.;Georgina Espígol-Frigolé.;Maria C Cid.;Guillermo Ruiz-Irastorza.
来源: Rheumatology (Oxford). 2026年65卷1期
Treatment of GCA still requires substantial exposure to glucocorticoids (GCs), which are associated with significant toxicity. This study compares the efficacy and safety of the GC-only standard of care (SOC) with a regimen combining intravenous methylprednisolone (IVMP) pulses, MTX and lower doses of prednisone, in newly diagnosed patients with GCA.
188. Elevated pre-eclampsia risk in lupus nephritis and antiphospholipid syndrome: a nationwide Spanish registry analysis.
作者: Mario Martín-Portugués.;Jorge Esteban-Sampedro.;Susana Mellor-Pita.;Pablo Tutor de Ureta.;Román Fernández-Guitián.;Ana Huerta.;Guillermo Ruiz-Irastorza.;Luis Dueña-Bartolome.;Ana Royuela.;Alfonso Ortega-de la Puente.;Marina de la Cruz-Echeandía.;Víctor Moreno-Torres.
来源: Rheumatology (Oxford). 2026年65卷1期
Evaluate the association of APS and SLE, focusing on LN, with risk of pre-eclampsia (PE) and PE with severity criteria (PESC).
189. Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis.
作者: Helena Marzo-Ortega.;Iain B McInnes.;Mohamed Sharaf.;Alen Zabotti.;Emmanouil Rampakakis.;Dennis McGonagle.;Ahmed Abogamal.;Pascal Richette.;Georg Schett.
来源: Rheumatology (Oxford). 2026年65卷1期
To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR).
191. Facilitators influencing participation in digitally-based high-intensity interval training among individuals with axial spondyloarthritis - a qualitative study.
作者: Anna Torell.;Emelie Wiking.;Ingrid Larsson.;M Charlotte Olsson.;Emma Haglund.
来源: BMC Rheumatol. 2025年9卷1期104页
Physical exercise is part of the recommended treatment for individuals with axial spondyloarthritis (axSpA). High-intensity interval training (HIIT) is an effective way to improve cardiovascular health without risk of increased disease activity. Nevertheless, there is a lack of knowledge regarding facilitating factors for digitally-based HIIT among individuals with axSpA.
192. Impact of hand function impairment on daily life of patients with systemic sclerosis: a qualitative study.
作者: Mark Greveling.;Stefano Rodolfi.;Nora El Bardai.;Christopher P Denton.;Voon H Ong.;Nick Jeffries-Owen.;Rita Schriemer.;Lieke Tweehuysen.;Julia Spierings.
来源: Rheumatology (Oxford). 2026年65卷1期
Many patients with systemic sclerosis (SSc) experience impaired hand function, yet the precise nature and impact of this impairment remains unclear. In this study, we explored the determinants of hand function impairment in SSc from a patient perspective and its impact on daily life. Additionally, we identified unmet care needs related to hand function impairment.
193. Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.
作者: Edoardo Cipolletta.;Georgina Nakafero.;Davide Rozza.;Satveer K Mahil.;Catherine H Smith.;Richard D Riley.;Abhishek Abhishek.
来源: Lancet Rheumatol. 2025年7卷12期e840-e850页
Allopurinol, the most prescribed urate-lowering drug, is a known cause of severe cutaneous adverse reactions. We aimed to develop and validate a model to assess the risk of allopurinol-induced severe cutaneous adverse reactions in adults newly prescribed allopurinol.
194. Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry.
作者: Francesco Bonomi.;Cosimo Bruni.;Silvia Peretti.;Rossella De Angelis.;Gianluigi Bajocchi.;Dilia Giuggioli.;Martina Orlandi.;Giovanni Zanframundo.;Rosario Foti.;Giovanna Cuomo.;Alarico Ariani.;Edoardo Rosato.;Gemma Lepri.;Francesco Girelli.;Valeria Riccieri.;Elisabetta Zanatta.;Silvia Laura Bosello.;Ilaria Cavazzana.;Francesca Ingegnoli.;Maria De Santis.;Fabio Cacciapaglia.;Giuseppe Murdaca.;Giuseppina Abignano.;Pettiti Giorgio.;Alessandra Della Rossa.;Maurizio Caminiti.;Anna Maria Iuliano.;Giovanni Ciano.;Lorenzo Beretta.;Gianluca Bagnato.;Ennio Lubrano.;Ilenia De Andres.;Luca Idolazzi.;Marta Saracco.;Cecilia Agnes.;Corrado Campochiaro.;Edoardo Cipolletta.;Marco Fornaro.;Federica Lumetti.;Amelia Spinella.;Luca Magnani.;Giacomo De Luca.;Veronica Codullo.;Elisa Visalli.;Carlo Iandoli.;Antonietta Gigante.;Greta Pellegrino.;Erika Pigatto.;Maria Grazia Lazzaroni.;Enrico De Lorenzis.;Gianna Mennillo.;Marco Di Battista.;Giuseppa Pagano-Mariano.;Federica Furini.;Licia Vultaggio.;Simone Parisi.;Clara Lisa Peroni.;Gerolamo Bianchi.;Enrico Fusaro.;Gian Domenico Sebastiani.;Marcello Govoni.;Salvatore D'Angelo.;Franco Cozzi.;Franco Franceschini.;Serena Guiducci.;Lorenzo Dagna.;Andrea Doria.;Carlo Salvarani.;Maria Antonietta D'Agostino.;Florenzo Iannone.;Clodoveo Ferri.;Marco Matucci-Cerinic.;Silvia Bellando Randone.; .
来源: Rheumatology (Oxford). 2026年65卷1期
To describe the prevalence of gastrointestinal (GI) symptoms in SSc and Very Early Diagnosis of SSc (VEDOSS), identify clinical and serological features associated with GI involvement and explore a cranio-caudal pattern of symptom distribution, using data from the Italian SPRING-SIR registry.
195. A new characteristic of SLE: subclinical vein involvement-an in-depth biochemical and imaging study.
作者: Derya Yildirim.;Abdulsamet Erden.;Nemat Ibrahimkhanli.;Elena Elefante.;Rahime Duran.;Handenur Koc Kanik.;Rıza Can Kardas.;İbrahim Vasi.;Hazan Karadeniz.;Mahinur Cerit.;Halit Nahit Sendur.;Marta Mosca.;Hamit Kucuk.;Mehmet Akif Ozturk.;Abdurrahman Tufan.
来源: Rheumatology (Oxford). 2026年65卷1期
SLE is a heterogeneous autoimmune disorder often complicated by vascular events, with or without antiphospholipid antibody syndrome (APS). This study aimed to explore subclinical venous involvement in SLE using biochemical and imaging modalities, focusing on vein wall thickness (VWT) and inflammation-related biomarkers.
197. Early-onset systemic lupus erythematosus-ANCA-associated vasculitis overlap syndrome caused by DNASE1L3 deficiency.
作者: Clément Triaille.;Sohei Makita.;Kévin Côté.;Geneviève Benoit.;Philippe M Campeau.;Jean Jacques De Bruycker.;Ai Ra.;Jon J McCord.;Khampoun Sayasith.;R Bryan Sutton.;Fabien Touzot.;Elie Haddad.;Boris Reizis.;Marie-Paule Morin.
来源: Rheumatology (Oxford). 2025年64卷12期6432-6434页 199. The impact of virtual rheumatology care on patient outcomes and hospital admissions: an ambispective study.
作者: Ummugulsum Gazel.;Tommy Han.;Seyyid Bilal Acikgoz.;Tara Swami.;Ricardo Sabido-Sauri.;Hart Goldhar.;Nataliya Milman.;Nancy Maltez.;Catherine Ivory.;Susan Humphrey-Murto.;Sibel Aydin.
来源: BMC Rheumatol. 2025年9卷1期103页
The impact of virtual care on clinical outcomes, healthcare resources and long-term patient satisfaction will help to inform healthcare providers. We aimed to evaluate the impact of virtual rheumatology care on patients’ clinical outcomes and healthcare utilization.
200. The evolving landscape of rheumatic drugs and their indications in paediatric and adolescent care.
作者: Coziana Ciurtin.;Mihaela Sparchez.;Despina Elephtheriou.;Paul Brogan.
来源: Rheumatology (Oxford). 2025年64卷12期6048-6070页
Paediatric rheumatic diseases (RMDs) are characterized by dysregulation of the immune system functions due to a combination of genetic, epigenetic and environmental factors. In many cases, children and young people (CYP) with RMDs require long-term pharmacological interventions to control their symptoms, minimize the risk of disease relapse and organ damage and ultimately preserve their quality of life. The past decades have seen significant progress in the expansion of therapeutic options licensed or available off-license for CYP with RMDs, and an unprecedented number of paediatric interventional clinical trials testing new therapies. This review aims to appraise the paediatric rheumatology community on available pharmacological therapies for use in childhood-onset RMDs, including conventional, biologic and targeted synthetic disease modifying anti-rheumatic drugs, immunoglobulins and cell-based therapies, highlighting their known indications, as well as current guidelines and consensus recommendations supporting their use off-license. We review the paediatric dosing regimens available for the treatment of RMDs and other autoimmune conditions, the toxicity profile of available therapeutic agents and provide a comprehensive evaluation of emerging therapies for childhood RMDs, currently tested in clinical trials.
|